Caterina P. Minniti
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Caterina P. Minniti has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
M. Catherine Driscoll
Division of Hematology/Oncology, Children's National Medical Center, Washington, District of Columbia
2 shared publications- Barbara Speller-Brown
Division of Hematology Children's National Hospital Washington District of Columbia USA
1 shared publication Dorothy Bulas
Division of Radiology, Children's National Medical Center, Washington, District of Columbia
1 shared publicationMarijean Miller
Ophthalmology
1 shared publicationMichael Henry
Department of Hematology/Oncology, Children's National Medical Center, Washington, DC 20010, USA
1 shared publicationRobert McCarter
1 shared publication
Latest Publications
- 8 March 2006
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 47 (7) , 894-900
Hydroxyurea therapy lowers TCD velocities in children with sickle cell disease
Introduction: Hydroxyurea (HU) improves hematologic parameters and decreases adverse events in patients with sickle cell disease (SCD). HU has been proposed as an alternative to chronic transfusions for secondary stroke prevention. Transcranial doppler (TCD) is an accepted method of stroke risk stratification in patients with SCD. We sought to determine if HU affects TCD velocities in children with SCD.Methods: A cohort of 24 children with HbSS with a baseline TCDi prior to HU and a follow‐up after at least 6 months of therapy was analyzed. Twenty‐four age‐matched children with HbSS formed the control group. Differences in hematologic parameters before and after HU therapy were evaluated.Results: TCDi velocities decreased in the HU‐treated patients. The adjusted mean change in TCDi velocities was −13.0 cm/sec (95% CI −20.19, −5.92) in the HU‐treated group and +4.72 cm/sec (95% CI −3.24, 12.69) in the controls. Changes in TCDi between the two groups were statistically significant (P < 0.001). Changes in hematologic parameters were not predictive of changes in TCDi velocities in the treated patients. Four out of five patients with TCDi velocities >170 cm/sec had normalization of TCDi velocities on HU. Mean change was −34.75 cm/sec in this subgroup. No patients experienced cerebrovascular accidents (CVA) while on HU.Conclusions: HU‐treated patients experienced statistically significant decreases in TCDi velocities compared to age‐matched controls. Changes in hematologic parameters were not predictive of changes in TCDi velocities in the treated group. The decrease in TCDi velocities is not a consequence of changes in hematologic values in patients treated with HU. Pediatr Blood Cancer
- 8 March 2006
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 47 (7) , 894-900
Hydroxyurea therapy lowers TCD velocities in children with sickle cell disease
Introduction: Hydroxyurea (HU) improves hematologic parameters and decreases adverse events in patients with sickle cell disease (SCD). HU has been proposed as an alternative to chronic transfusions for secondary stroke prevention. Transcranial doppler (TCD) is an accepted method of stroke risk stratification in patients with SCD. We sought to determine if HU affects TCD velocities in children with SCD.Methods: A cohort of 24 children with HbSS with a baseline TCDi prior to HU and a follow‐up after at least 6 months of therapy was analyzed. Twenty‐four age‐matched children with HbSS formed the control group. Differences in hematologic parameters before and after HU therapy were evaluated.Results: TCDi velocities decreased in the HU‐treated patients. The adjusted mean change in TCDi velocities was −13.0 cm/sec (95% CI −20.19, −5.92) in the HU‐treated group and +4.72 cm/sec (95% CI −3.24, 12.69) in the controls. Changes in TCDi between the two groups were statistically significant (P < 0.001). Changes in hematologic parameters were not predictive of changes in TCDi velocities in the treated patients. Four out of five patients with TCDi velocities >170 cm/sec had normalization of TCDi velocities on HU. Mean change was −34.75 cm/sec in this subgroup. No patients experienced cerebrovascular accidents (CVA) while on HU.Conclusions: HU‐treated patients experienced statistically significant decreases in TCDi velocities compared to age‐matched controls. Changes in hematologic parameters were not predictive of changes in TCDi velocities in the treated group. The decrease in TCDi velocities is not a consequence of changes in hematologic values in patients treated with HU. Pediatr Blood Cancer
- 1 March 2004
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 113 (3) , e265-e269
Pseudotumor Cerebri in Children With Sickle Cell Disease: A Case Series
Headache is a frequent symptom in sickle cell disease (SCD) that usually is attributable to anemia or cerebrovascular disease. We report 3 pediatric patients with SCD (1 patient with SCD-SC and 2 patients with SCD-SS) who presented with headache and were diagnosed with pseudotumor cerebri (PC). All 3 patients had elevated opening pressures during a lumbar puncture with normal cerebrospinal fluid studies. Magnetic resonance imaging revealed no evidence of hydrocephalus or arteriopathy in all 3 cases. Magnetic resonance venograms performed in 2 of the patients at diagnosis revealed no evidence of cerebral sinus thrombosis. Each patient received a thorough ophthalmologic examination. A diagnostic funduscopic examination revealed bilateral papilledema without signs of retinopathy in all 3 patients. There were no clinically significant changes in visual acuity or abnormalities of color vision in any patient. Goldmann or Humphrey visual-field assessment was abnormal only in patient 1, who demonstrated bilaterally enlarged blind spots at diagnosis and later developed reduced sensitivity in the inferomedial quadrant of the left eye in an arcuate pattern (which later resolved). The diagnosis of PC was made in all 3 patients, and acetazolamide treatment was started. Two of the patients’ symptoms resolved completely with medical treatment, whereas the third patient’s symptoms improved. None of these patients had permanent visual-field deficits as a result of their syndrome. PC has been reported in several other types of anemia including SCD-SC, but these cases are the first reported in conjunction with pediatric SCD. Early recognition of the signs and symptoms of PC in patients with SCD who present with headache can expedite proper diagnosis and treatment and prevent long-term ophthalmologic sequelae.
- 1 March 2004
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 113 (3) , e265-e269
Pseudotumor Cerebri in Children With Sickle Cell Disease: A Case Series
Headache is a frequent symptom in sickle cell disease (SCD) that usually is attributable to anemia or cerebrovascular disease. We report 3 pediatric patients with SCD (1 patient with SCD-SC and 2 patients with SCD-SS) who presented with headache and were diagnosed with pseudotumor cerebri (PC). All 3 patients had elevated opening pressures during a lumbar puncture with normal cerebrospinal fluid studies. Magnetic resonance imaging revealed no evidence of hydrocephalus or arteriopathy in all 3 cases. Magnetic resonance venograms performed in 2 of the patients at diagnosis revealed no evidence of cerebral sinus thrombosis. Each patient received a thorough ophthalmologic examination. A diagnostic funduscopic examination revealed bilateral papilledema without signs of retinopathy in all 3 patients. There were no clinically significant changes in visual acuity or abnormalities of color vision in any patient. Goldmann or Humphrey visual-field assessment was abnormal only in patient 1, who demonstrated bilaterally enlarged blind spots at diagnosis and later developed reduced sensitivity in the inferomedial quadrant of the left eye in an arcuate pattern (which later resolved). The diagnosis of PC was made in all 3 patients, and acetazolamide treatment was started. Two of the patients’ symptoms resolved completely with medical treatment, whereas the third patient’s symptoms improved. None of these patients had permanent visual-field deficits as a result of their syndrome. PC has been reported in several other types of anemia including SCD-SC, but these cases are the first reported in conjunction with pediatric SCD. Early recognition of the signs and symptoms of PC in patients with SCD who present with headache can expedite proper diagnosis and treatment and prevent long-term ophthalmologic sequelae.